Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies

Francesca Zammarchi, Karin E. Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, Francois Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A. Hartley, Patrick H. van Berkel

Mol Cancer Ther (2024) 23 (4): 520–531.

https://doi.org/10.1158/1535-7163.MCT-23-0506

Published: 02 April 2024

View article titled, ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies

Includes: Supplementary data

Journal Articles

Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody–Drug Conjugate Efficacy and Toxicity

Arnaud C. Tiberghien, Balakumar Vijayakrishnan, Arman Esfandiari, Mahammad Ahmed, Raul Pardo, John Bingham, Lauren Adams, Kathleen Santos, Gyoung-Dong Kang, Kathryn M. Pugh, Shameen Afif-Rider, Kapil Vashisht, Kemal Haque, Ravinder Tammali, Edward Rosfjord, Adriana Savoca, John A. Hartley, Philip W. Howard

Mol Cancer Ther (2023) 22 (2): 254–263.

https://doi.org/10.1158/1535-7163.MCT-21-0693

Published: 01 February 2023

View article titled, Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody–Drug Conjugate Efficacy and Toxicity

Includes: Supplementary data

Journal Articles

Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer

Stephen J. Gregson, Kathryn Pugh, Neki Patel, Shameen Afif-Rider, Balakumar Vijayakrishnan, Kathleen Santos, Jitka Riedl, Ian Hutchinson, Gyoung-Dong Kang, K. Phin Chooi, Rhiannon Beard, Lauren Adams, Conor S. Barry, Kathryn Ball, Luke A. Masterson, Mary McFarlane, John A. Hartley, Philip W. Howard

Mol Cancer Ther (2022) 21 (9): 1439–1448.

https://doi.org/10.1158/1535-7163.MCT-22-0145

Published: 06 September 2022

View article titled, Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer

Includes: Supplementary data

Journal Articles

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers

Francesca Zammarchi, Karin EG. Havenith, Simon Chivers, Paul Hogg, Francois Bertelli, Peter Tyrer, Narinder Janghra, Halla W. Reinert, John A. Hartley, Patrick H. van Berkel

Mol Cancer Ther (2022) 21 (4): 582–593.

https://doi.org/10.1158/1535-7163.MCT-21-0715

Published: 01 April 2022

View article titled, Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers

Includes: Supplementary data

Journal Articles

The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer–Containing Antibody–Drug Conjugates

Simon Corbett, Shiran Huang, Francesca Zammarchi, Philip W. Howard, Patrick H. van Berkel, John A. Hartley

Mol Cancer Ther (2020) 19 (9): 1856–1865.

https://doi.org/10.1158/1535-7163.MCT-20-0222

Published: 02 September 2020

View article titled, The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer–Containing Antibody–Drug Conjugates

Includes: Supplementary data

Journal Articles

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Mol Cancer Ther (2018) 17 (10): 2176–2186.

https://doi.org/10.1158/1535-7163.MCT-17-0982

Published: 01 October 2018

View article titled, Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Includes: Supplementary data

Journal Articles

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Michael J. Flynn, Francesca Zammarchi, Peter C. Tyrer, Ayse U. Akarca, Narinder Janghra, Charles E. Britten, Carin E.G. Havenith, Jean-Noel Levy, Arnaud Tiberghien, Luke A. Masterson, Conor Barry, Francois D'Hooge, Teresa Marafioti, Paul W.H.I. Parren, David G. Williams, Philip W. Howard, Patrick H. van Berkel, John A. Hartley

Mol Cancer Ther (2016) 15 (11): 2709–2721.

https://doi.org/10.1158/1535-7163.MCT-16-0233

Published: 01 November 2016

View article titled, ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Includes: Supplementary data

Journal Articles

Abstract C51: Chemosensitisation to cisplatin by STAT3 inhibitors is mediated through the inhibition of DNA interstrand crosslink unhooking

Helen Valentine, Emily Dixon, John A. Hartley, Konstantinos Kiakos

Mol Cancer Ther (2015) 14 (12_Supplement_2): C51.

https://doi.org/10.1158/1535-7163.TARG-15-C51

Published: 01 December 2015

View article titled, Abstract C51: Chemosensitisation to cisplatin by STAT3 inhibitors is mediated through the inhibition of DNA interstrand crosslink unhooking

Journal Articles

Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase IIα Expression

Jaishree Bhosle, Konstantinos Kiakos, Andrew C.G. Porter, Jenny Wu, Andreas Makris, John A Hartley, Daniel Hochhauser

Mol Cancer Ther (2013) 12 (12): 2897–2908.

https://doi.org/10.1158/1535-7163.MCT-12-1049

Published: 05 December 2013

View article titled, Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase IIα Expression

Includes: Supplementary data

Journal Articles

Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents

Julien J.M. Boone, Jaishree Bhosle, Mike J. Tilby, John A. Hartley, Daniel Hochhauser

Mol Cancer Ther (2009) 8 (11): 3015–3023.

https://doi.org/10.1158/1535-7163.MCT-09-0219

Published: 10 November 2009

View article titled, Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents

Journal Articles

Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78

Minal Kotecha, Jerome Kluza, Geoff Wells, C. Caroline O'Hare, Claudia Forni, Roberto Mantovani, Philip W. Howard, Peter Morris, David E. Thurston, John A. Hartley, Daniel Hochhauser

Mol Cancer Ther (2008) 7 (5): 1319–1328.

https://doi.org/10.1158/1535-7163.MCT-07-0475

Published: 15 May 2008

View article titled, Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78

Journal Articles

DNA sequence–selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e]indolone analogue of duocarmycin AS-I-145

Konstantinos Kiakos, Atsushi Sato, Tetsuji Asao, Peter J. McHugh, Moses Lee, John A. Hartley

Mol Cancer Ther (2007) 6 (10): 2708–2718.

https://doi.org/10.1158/1535-7163.MCT-07-0294

Published: 15 October 2007

View article titled, DNA sequence–selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e]indolone analogue of duocarmycin AS-I-145

Journal Articles

Modulation of topoisomerase IIα expression by a DNA sequence-specific polyamide

Daniel Hochhauser, Minal Kotecha, Caroline O'Hare, Peter J. Morris, Janet M. Hartley, Zarmeen Taherbhai, Dorothy Harris, Claudia Forni, Roberto Mantovani, Moses Lee, John A. Hartley

Mol Cancer Ther (2007) 6 (1): 346–354.

https://doi.org/10.1158/1535-7163.MCT-06-0503

Published: 19 January 2007

View article titled, Modulation of topoisomerase IIα expression by a DNA sequence-specific polyamide

Journal Articles

Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling

Stéphanie Arnould, Victoria J. Spanswick, Janet S. Macpherson, John A. Hartley, David E. Thurston, Duncan I. Jodrell, Sylvie M. Guichard

Mol Cancer Ther (2006) 5 (6): 1602–1609.

https://doi.org/10.1158/1535-7163.MCT-06-0018

Published: 03 July 2006

View article titled, Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling

Journal Articles

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment

Benjamin J. Friedmann, Martyn Caplin, Boris Savic, Tahir Shah, Christopher J. Lord, Alan Ashworth, John A. Hartley, Daniel Hochhauser

Mol Cancer Ther (2006) 5 (2): 209–218.

https://doi.org/10.1158/1535-7163.MCT-05-0239

Published: 27 February 2006

View article titled, Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment

NARROW

ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies

Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody–Drug Conjugate Efficacy and Toxicity

Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers

The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer–Containing Antibody–Drug Conjugates

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Abstract C51: Chemosensitisation to cisplatin by STAT3 inhibitors is mediated through the inhibition of DNA interstrand crosslink unhooking

Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase IIα Expression

Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents

Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78

DNA sequence–selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e]indolone analogue of duocarmycin AS-I-145

Modulation of topoisomerase IIα expression by a DNA sequence-specific polyamide

Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only